August 05, 2026
A Texas federal judge has denied Revive Rx's bid to end Eli Lilly and Co.'s remaining unfair-competition claims over the compounding pharmacy's sales of allegedly unapproved tirzepatide weight-loss drugs that Eli Lilly says compete with Mounjaro and Zepbound, rejecting Revive's argument that compounded drugs fall outside state "new drug" laws.
September 19, 2023
A little more than a year after releasing a popular billion-dollar drug marketed at people with Type 2 diabetes, Eli Lilly & Co. filed a flurry of lawsuits on Tuesday against spas and other retailers that it says are selling counterfeit or compounded versions of the drug as a weight loss cure.